Clemens Scherzer
Affiliations: | Harvard Medical School, Boston, MA, United States |
Area:
Translational Genomics of Parkinson’s Disease: Cause, Cures, DiagnosticsGoogle:
"Clemens Scherzer"Mean distance: 106866
Parents
Sign in to add mentor| David G. Standaert | research scientist | 2001-2002 | Harvard Medical School - Beth Israel Deaconess Medical Center |
Children
Sign in to add trainee| Xianjun Dong | research scientist | 2013- | Harvard Medical School - Brigham and Women's Hospital (Chemistry Tree) |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Romanowska J, Bjornevik K, Cortese M, et al. (2023) Association Between Use of Any of the Drugs Prescribed in Norway and the Subsequent Risk of Parkinson Disease: A Drug-wide Association Study. Neurology. 101: e2068-e2077 |
| Dong X, Bai Y, Liao Z, et al. (2023) Circular RNAs in the human brain are tailored to neuron identity and neuropsychiatric disease. Nature Communications. 14: 5327 |
| Giladi N, Alcalay RN, Cutter G, et al. (2023) Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet. Neurology. 22: 661-671 |
| Huh YE, Usnich T, Scherzer CR, et al. (2023) Variants and Parkinson's Disease: Paving the Way for Targeted Therapy. Journal of Movement Disorders |
| Dong X, Bai Y, Liao Z, et al. (2023) Circular RNAs in the human brain are tailored to neuron identity and neuropsychiatric disease. Biorxiv : the Preprint Server For Biology |
| Fonseca-Ornelas L, Stricker JMS, Soriano-Cruz S, et al. (2022) Parkinson-causing mutations in LRRK2 impair the physiological tetramerization of endogenous α-synuclein in human neurons. Npj Parkinson's Disease. 8: 118 |
| Bivol S, Mellick GD, Gratten J, et al. (2022) Australian Parkinson's Genetics Study (APGS): pilot (n=1532). Bmj Open. 12: e052032 |
| Szwedo AA, Dalen I, Pedersen KF, et al. (2022) GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based Study. Movement Disorders : Official Journal of the Movement Disorder Society |
| Peterschmitt MJ, Saiki H, Hatano T, et al. (2021) Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial. Journal of Parkinson's Disease |
| Huh YE, Park H, Chiang MSR, et al. (2021) Glucosylceramide in cerebrospinal fluid of patients with GBA-associated and idiopathic Parkinson's disease enrolled in PPMI. Npj Parkinson's Disease. 7: 102 |